Auris Medical's tinnitus drug misses main goals in study

[August 18, 2016]  (Reuters) - Auris Medical Holding AG said on Thursday its experimental drug for acute inner ear tinnitus missed the main goals of a late-stage study.

The trial did not meet the two co-primary effectiveness goals of statistically significant changes in tinnitus loudness and tinnitus burden compared to a placebo, the company said.

Auris said results from a second late-stage trial are expected in the fourth quarter.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)

[© 2016 Thomson Reuters. All rights reserved.]

Copyright 2016 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.